Seminars in Oncology
Volume 30, Issue 5 , Pages 587-595 , October 2003

Conservative versus radical therapy of prostate cancer: how have recent advances in molecular markers and imaging enhanced our ability to prognosticate risk?

  • Scott Bagnall

      Affiliations

    • Sunnybrook & Women’s College Health Sciences Centre, Toronto, Canada
    • ,
  • Laurence Klotz

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Laurence Klotz, MD, Sunnybrook & Women’s College Health Sciences Centre, 2075 Bayview Ave #MG 408, Toronto, Ontario M4N 3M5, Canada
    • Sunnybrook & Women’s College Health Sciences Centre, Toronto, Canada

References 

  1. Johansson J, Adami H, Andersson S. High 10 year survival rate in patients with early, untreated prostatic cancer. JAMA. 1992;267:2191–2196
  2. Johansson J, Johansson LH. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA. 1997;277:467–471
  3. Hanash K, Utz DC, Cook EN. Carcinoma of the prostate (A 15 year followup). J Urol. 1972;107:450–453
  4. Cook G, Watson FR. Twenty nodules of prostate cancer not treated by total prostatecotmy. J Urol. 1968;100:672–674
  5. Barnes R, Hirst A, Rosenquist R. Early carcinoma of the prostate (Comparison of stages A and B). J Urol. 1976;115:404–405
  6. Lerner S, Seale-Hawkins C, Carlton CE, et al.  The risk of dying of prostate cancer in patients with clinically localized disease. J Urol. 1991;146:1040–1045
  7. Handley R, Carr TW, Travis D, et al.  Deferred treatment for prostate cancer. Br I Urol. 1988;62:249–253
  8. Adolfsson J, Cartensen J, Lowhagen T. Deferred treatment in clinically localized prostate carcinoma. Br J Urol. 1992;69:183–187
  9. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet. 1997;349:906–910
  10. Holmberg L, Bill-Axelson A, Helgesen F, et al.  A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002;347:781–789
  11. Waaler G, Stenwig AE. Prognosis of localised prostatic cancer managed by “watch and wait” policy. Br I Urol. 1993;72:214–219
  12. Whitmore W, Waarner IA, Thompson IM. Expectant management of localized prostatic cancer. Cancer. 1991;67:1091–1096
  13. George N. Natural history of localised prostatic cancer managed by conservative therapy alone. Lancet. 1988;1:494–496
  14. Aus G, Hugosson I, Norlen L. Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol. 1995;154:460–465
  15. Sandblom G, Dufmats M, Varenhorst E. Long-term survival in a Swedish population-based cohort of men with prostate cancer. Urology. 2000;56:442–447
  16. Madsen P, Graversen PH, Gasser TC, et al.  Treatment of localized prostatic cancer. Radical prostatectomy versus placebo: A 15-year follow-up. Scand J Urol Nephrol. 1988;110(suppl):95–100
  17. Leek J, Lench N, Maraj B, et al.  Prostate-specific membrane antigen (Evidence for the existence of a second related human gene). Br J Cancer. 1995;72:583–588
  18. Su SL, Huang IP, Fair WR, et al.  Alternatively spliced variants of prostate-specific membrane antigen RNA (Ratio of expression as a potential measurement of progression). Cancer Res. 1995;55:1441–1443
  19. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987;7:927–935
  20. Lopes AD, Davis WL, Rosenstraus MJ, et al.  Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. Cancer Res. 1990;50:6423–6429
  21. Murphy GP, Elgamal AA, Su SL, et al.  Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer. 1998;83:2259–2269
  22. Kawakami M, Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res. 1997;57:2321–2324
  23. Moreno JG, Croce CM, Fischer R, et al.  Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res. 1992;52:6110–6112
  24. Grauer LS, Lawler KD, Marignac JL, et al.  Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM′ protein in the LNCaP prostatic carcinoma cell line. Cancer Res. 1998;58:4787–4789
  25. Murphy GP, Greene TG, Tino WT, et al.  Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. J Urol. 1998;160:2396–2401
  26. Kahn D, Williams RD, Manyak MJ, et al.  111 Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. J Urol. 1998;159:2041–2046
  27. Elgamal AA, Troychak MJ, Murphy GP. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy (Analysis of 136 scans of 100 patients). Prostate. 1998;37:261–269
  28. Zhang S, Zhang HS, Reuter VE, et al.  Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res. 1998;4:295–302
  29. Zhang S, Zhang HS, Cordon-Cardo C, et al.  Selection of tumor antigens as targets for immune attack using immunohistochemistry (Protein antigens). Clin Cancer Res. 1998;4:2669–2676
  30. Tjoa BA, Simmons SJ, Bowes VA, et al.  Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate. 1998;36:39–44
  31. Murphy GP, Tjoa BA, Simmons SJ, et al.  Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients. Prostate. 2000;43:59–62
  32. Gong MC, Latouche JB, Krause A, et al.  Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia. 1999;1:123–127
  33. Renneberg H, Friedetzky A, Konrad L, et al.  Prostate specific membrane antigen (PSM) is expressed in various human tissues (Implication for the use of PSM reverse transcription polymerase chain reaction to detect hematogenous prostate cancer spread). Urol Res. 1999;27:23–27
  34. Israeli RS, Powell CT, Corr JG, et al.  Expression of the prostate-specific membrane antigen. Cancer Res. 1994;54:1807–1811
  35. Lintula S, Stenman UH. The expression of prostate-specific membrane antigen in peripheral blood leukocytes. J Urol. 1997;157:1969–1972
  36. Llanes L, Ferruelo A, Paez A, et al.  The clinical utility of the prostate specific membrane antigen reverse-transcription/polymerase chain reaction to detect circulating prostate cells (An analysis in healthy men and women). BJU Int. 2002;89:882–885
  37. Hara N, Kasahara T, Kawasaki T, et al.  Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood (Value for the staging of prostate cancer). Clin Cancer Res. 2002;8:1794–1799
  38. Woodrum DL, French CM, Hill TM, et al.  Analytical performance of the Tandem-R free PSA immunoassay measuring free prostate-specific antigen. Clin Chem. 1997;43:1203–1208
  39. Takayama TK, Fujikawa K, Davie EW. Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. J Biol Chem. 1997;272:21582–21588
  40. Young CY, Andrews PE, Montgomery BT, et al.  Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry. 1992;31:818–824
  41. Partin AW, Catalona WJ, Finlay JA, et al.  Use of human glandular kallikrein 2 for the detection of prostate cancer (preliminary analysis). Urology. 1999;54:839–845
  42. Nam RK, Diamandis EP, Toi A, et al.  Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J Clin Oncol. 2000;18:1036–1042
  43. Tremblay RR, Deperthes D, Tetu B, et al.  Immunohistochemical study suggesting a complementary role of kallikreins hK2 and hK3 (prostate-specific antigen) in the functional analysis of human prostate tumors. Am J Pathol. 1997;150:455–459
  44. Darson MF, Pacelli A, Roche P, et al.  Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma (a novel prostate cancer marker). Urology. 1997;49:857–862
  45. Scorilas A, Plebani M, Mazza S, et al.  Serum human glandular kalllikrein and insulin-like growth factor 1 improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and % free PSA. Prostate. 2003;54:220–229
  46. Magklara A, Scorilas A, Catalona WJ, et al.  The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clin Chem. 1999;45:1960–1966
  47. Yu JX, Chao L, Chao J. Prostasin is a novel human serine proteinase from seminal fluid. Purification, tissue distribution, and localization in prostate gland. J Biol Chem. 1994;269:18843–18848
  48. Takeuchi T, Shuman MA, Craik CS. Reverse biochemistry (Use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue). Proc Natl Acad Sci USA. 1999;96:11054–11061
  49. Rittenhouse HG, Finlay JA, Mikolajczyk SD, et al.  Human kallikrein 2 (hK2) and prostate-specific antigen (PSA) (Two closely related, but distinct, kallikreins in the prostate). Crit Rev Clin Lab Sci. 1998;35:275–368
  50. Dhanasekaran SM, Barrette TR, Ghosh D, et al.  Delineation of prognostic biomarkers in prostate cancer. Nature. 2001;412:822–826
  51. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins (Biological actions). Endocr Rev. 1995;16:3–34
  52. Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids (Regulation and functions). Endocr Rev. 1997;18:801–831
  53. Rajah R, Katz L, Nunn S, et al.  Insulin-like growth factor binding protein (IGFBP) proteases (Functional regulators of cell growth). Prog Growth Factor Res. 1995;6:273–284
  54. Baserga R. The insulin-like growth factor I receptor (A key to tumor growth?). Cancer Res. 1995;55:249–252
  55. Chan JM, Stampfer MJ, Giovannucci E, et al.  Plasma insulin-like growth factor-I and prostate cancer risk (a prospective study). Science. 1998;279:563–566
  56. Bok RA, Small EJ. Bloodborne biomolecular markers in prostate cancer development and progression. Nat Rev Cancer. 2002;2:918–926
  57. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol. 2001;19:1207–1225
  58. Weidner N, Carroll PR, Flax J, et al.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143:401–409
  59. Nelson JB, Hedican SP, George DJ, et al.  Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995;1:944–949
  60. Battistini B, D’Orleans-Juste P, Sirois P. Endothelins (Circulating plasma levels and presence in other biologic fluids). Lab Invest. 1993;68:600–628
  61. Chang F, Syrjanen S, Syrjanen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol. 1995;13:1009–1022
  62. Meyers FJ, Chi SG, Fishman JR, et al.  p53 mutations in benign prostatic hyperplasia. J Natl Cancer Inst. 1993;85:1856–1858
  63. Bookstein R, MacGrogan D, Hilsenbeck SG, et al.  p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res. 1993;53:3369–33673
  64. Dinjens WN, van der Weiden MM, Schroeder FH, et al.  Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int J Cancer. 1994;56:630–633
  65. Effert PJ, McCoy RH, Walther PJ, et al.  p53 gene alterations in human prostate carcinoma. J Urol. 1993;150:257–261
  66. Bauer JJ, Sesterhenn IA, Mostofi FK, et al.  Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol. 1996;156:1511–1516
  67. Quinn DI, Henshall SM, Head DR, et al.  Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res. 2000;60:1585–1594
  68. Huang A, Gandour-Edwards R, Rosenthal SA, et al.  p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy. Urology. 1998;51:346–351
  69. Grignon DJ, Caplan R, Sarkar FH, et al.  p53 status and prognosis of locally advanced prostatic adenocarcinoma (A study based on RTOG 8610). J Natl Cancer Inst. 1997;89:158–165
  70. Brewster SF, Oxley JD, Trivella M, et al.  ; Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol. 1999;161:1238–1243
  71. Stackhouse GB, Sesterhenn IA, Bauer JJ, et al.  p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol. 1999;162:2040–2045
  72. Ruijter E, van de Kaa C, Aalders T, et al.  Heterogeneous expression of E-cadherin and p53 in prostate cancer: Clinical implications. BIOMED-II Markers for Prostate Cancer Study Group. Mod Pathol. 1998;11:276–281
  73. Keshgegian AA, Johnston E, Cnaan A. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol. 1998;110:443–449
  74. Umbas R, Schalken JA, Aalders TW, et al.  Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res. 1992;52:5104–5109
  75. Bussemakers MJ, van Moorselaar RJ, Giroldi LA, et al.  Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res. 1992;52:2916–2922
  76. Kuczyk M, Machtens S, Hradil K, et al.  Predictive value of decreased p27Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients. Br J Cancer. 1999;81:1052–1058
  77. Adusumilli S, Pretorius ES. Magnetic resonance imaging of prostate cancer. Semin Urol Oncol. 2002;20:192–210
  78. Outwater EK, Petersen RO, Siegelman ES, et al.  Prostate carcinoma (Assessment of diagnostic criteria for capsular penetration on endorectal coil MR images). Radiology. 1994;193:333–339
  79. Hricak H, White S, Vigneron D, et al.  Carcinoma of the prostate gland (MR imaging with pelvic phased-array coils versus integrated endorectal-pelvic phased-array coils). Radiology. 1994;193:703–709
  80. Yu KK, Scheidler J, Hricak H, et al.  Prostate cancer (Prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging). Radiology. 1999;213:481–488
  81. Scheidler J, Hricak H, Vigneron DB, et al.  Prostate cancer (Localization with three-dimensional proton MR spectroscopic imaging—Clinicopathologic study). Radiology. 1999;213:473–480
  82. Swanson MG, Vigneron DB, Tran TK, et al.  Magnetic resonance imaging and spectroscopic imaging of prostate cancer. Cancer Invest. 2001;19:510–523
  83. Lu-Yao G, Albertsen PC, Stanford JL, et al.  Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ. 2002;325:740
  84. Sakr W, Haas GP, Cassin BF, et al.  The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol. 1993;150: 379–35
  85. Pound C, Partin EAW, Eisenberg MA, et al.  Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591–1597
  86. Kattan M, Zelefsky MJ, Kupelian PA, et al.  Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol. 2000;18:3352–3359
  87. Albertsen P, Hanley IA, Gleason DF, et al.  Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998;280:975–980
  88. Chodak G. The management of localized prostate cancer. J Urol. 1994;152:1766–1768
  89. Choo R, DeBoer G, Klotz L, et al.  PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys. 2001;50:615–620
  90. Choo R, Klotz L, Danjoux C, et al.  Feasibility study of watchful waiting for localized low to intermediate grade prostate cancer with selective delayed intervention based on PSA, histologic, and/or clinical progression. J Urol. 2002;167:1664–1669
  91. Klotz LH, Choo R, Morton G, et al.  Expectant management with selective delayed intervention for favorable-risk prostate cancer. Can J Urol. 2002;9(suppl 1):2–7
  92. Do V, Choo R, DeBoer G, et al.  The role of serial free/total prostate-specific antigen ratios in a watchful observation protocol for men with localized prostate cancer. Br J Urol Int. 2002;89:703–709
  93. Epstein JI, Walsh PC, Carter HB. Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. J Urol. 2001;166:1688–1691

PII: S0093-7754(03)00348-8

doi: 10.1016/S0093-7754(03)00348-8

Seminars in Oncology
Volume 30, Issue 5 , Pages 587-595 , October 2003

Article Tools

* Image Usage & Resolution